It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...

Higher-dose hydroxychloroquine in systemic lupus erythematosus is tied to lower risks for some cardiac conditions and no change in stroke, kidney, or cancer risks but higher eye risk in older adults.

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy in systemic lupus erythematosus vs. placebo, according to data published in ...

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...

New data identify age, anti-β2GP1 antibodies, and low C3 as key risk factors for cerebral small vessel disease in systemic ...

Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

How would you treat a 30-year-old woman with systemic lupus erythematous (SLE) and lupus nephritis (LN) class 3 with new ...

Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...